{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:17:10Z","timestamp":1790781430382,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T00:00:00Z","timestamp":1455667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Despite the ethical imperative to publish clinical trials when human subjects are involved, such data frequently remain unpublished. The objectives were to tabulate the rate and ascertain factors associated with eventual publication of clinical trial results reported as abstracts in the Proceedings of the American Society of Clinical Oncology (American Society of Clinical Oncology).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods.<\/jats:title>\n                  <jats:p>Abstracts describing clinical trials for patients with breast, lung, colorectal, ovarian, and prostate cancer from 2009 to 2011 were identified by using a comprehensive online database (http:\/\/meetinglibrary.asco.org\/abstracts). Abstracts included reported results of a treatment or intervention assessed in a discrete, prospective clinical trial. Publication status at 4\u22126 years was determined by using a standardized search of PubMed. Primary outcomes were the rate of publication for abstracts of randomized and nonrandomized clinical trials. Secondary outcomes included factors influencing the publication of results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>A total of 1,075 abstracts describing 378 randomized and 697 nonrandomized clinical trials were evaluated. Across all years, 75% of randomized and 54% of nonrandomized trials were published, with an overall publication rate of 61%. Sample size was a statistically significant predictor of publication for both randomized and nonrandomized trials (odds ratio [OR] per increase of 100 participants = 1.23 [1.11\u20131.36], p &amp;lt; .001; and 1.64 [1.15\u20132.34], p = .006, respectively). Among randomized studies, an industry coauthor or involvement of a cooperative group increased the likelihood of publication (OR 2.37, p = .013; and 2.21, p = .01, respectively). Among nonrandomized studies, phase II trials were more likely to be published than phase I (p &amp;lt; .001). Use of an experimental agent was not a predictor of publication in randomized (OR 0.76 [0.38\u20131.52]; p = .441) or nonrandomized trials (OR 0.89 [0.61\u20131.29]; p = .532).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>This is the largest reported study examining why oncology trials are not published. The data show that 4\u22126 years after appearing as abstracts, 39% of oncology clinical trials remain unpublished. Larger sample size and advanced trial phase were associated with eventual publication; among randomized trials, an industry-affiliated author or a cooperative group increased likelihood of publication. Unfortunately, we found that, despite widespread recognition of the problem and the creation of central data repositories, timely publishing of oncology clinical trials results remains unsatisfactory.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0516","type":"journal-article","created":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T01:22:30Z","timestamp":1455758550000},"page":"261-268","source":"Crossref","is-referenced-by-count":39,"title":["Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting"],"prefix":"10.1093","volume":"21","author":[{"given":"Paul R.","family":"Massey","sequence":"first","affiliation":[{"name":"a Dell Medical School, University of Texas at Austin, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibin","family":"Wang","sequence":"additional","affiliation":[{"name":"b Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"c Medical Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Bates","sequence":"additional","affiliation":[{"name":"c Medical Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito","family":"Fojo","sequence":"additional","affiliation":[{"name":"c Medical Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,2,17]]},"reference":[{"key":"2021122703520952500_B1","doi-asserted-by":"crossref","first-page":"f6104","DOI":"10.1136\/bmj.f6104","article-title":"Non-publication of large randomized clinical trials: Cross sectional analysis","volume":"347","author":"Jones","year":"2013","journal-title":"BMJ"},{"key":"2021122703520952500_B2","doi-asserted-by":"crossref","first-page":"e1001566; discussion e1001566","DOI":"10.1371\/journal.pmed.1001566","article-title":"Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals","volume":"10","author":"Riveros","year":"2013","journal-title":"PLoS Med"},{"key":"2021122703520952500_B3","doi-asserted-by":"crossref","first-page":"e1000144","DOI":"10.1371\/journal.pmed.1000144","article-title":"Trial publication after registration in ClinicalTrials.Gov: A cross-sectional analysis","volume":"6","author":"Ross","year":"2009","journal-title":"PLoS Med"},{"key":"2021122703520952500_B4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jama.280.3.250","article-title":"Publication bias and research on passive smoking: Comparison of published and unpublished studies","volume":"280","author":"Misakian","year":"1998","journal-title":"JAMA"},{"key":"2021122703520952500_B5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jama.1992.03480030052036","article-title":"Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards","volume":"267","author":"Dickersin","year":"1992","journal-title":"JAMA"},{"key":"2021122703520952500_B6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jama.279.4.281","article-title":"Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials","volume":"279","author":"Ioannidis","year":"1998","journal-title":"JAMA"},{"key":"2021122703520952500_B7","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2012.46.9460","article-title":"Off-label use of cancer drugs: A benchmark is established","volume":"31","author":"Krzyzanowska","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122703520952500_B8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/oxfordjournals.annonc.a058147","article-title":"The fate of abstracts submitted to a cancer meeting: Factors which influence presentation and subsequent publication","volume":"3","author":"De Bellefeuille","year":"1992","journal-title":"Ann Oncol"},{"key":"2021122703520952500_B9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jama.290.4.495","article-title":"Factors associated with failure to publish large randomized trials presented at an oncology meeting","volume":"290","author":"Krzyzanowska","year":"2003","journal-title":"JAMA"},{"key":"2021122703520952500_B10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/COC.0b013e3181845544","article-title":"Publication outcomes of phase II oncology clinical trials","volume":"32","author":"Hoeg","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"2021122703520952500_B11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/cncr.21337","article-title":"Presentation and subsequent publication rates of phase I oncology clinical trials","volume":"104","author":"Camacho","year":"2005","journal-title":"Cancer"},{"key":"2021122703520952500_B12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","article-title":"Publication bias in clinical research","volume":"337","author":"Easterbrook","year":"1991","journal-title":"Lancet"},{"key":"2021122703520952500_B13","doi-asserted-by":"crossref","first-page":"d7762","DOI":"10.1136\/bmj.d7762","article-title":"Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: A database survey","volume":"344","author":"Ahmed","year":"2012","journal-title":"BMJ"},{"key":"2021122703520952500_B14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(87)90155-3","article-title":"Publication bias and clinical trials","volume":"8","author":"Dickersin","year":"1987","journal-title":"Control Clin Trials"},{"key":"2021122703520952500_B15","first-page":"197","article-title":"Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee","volume":"138","author":"Von Elm","year":"2008","journal-title":"Swiss Med Wkly"},{"key":"2021122703520952500_B16","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1371\/journal.pmed.0050191","article-title":"Publication of clinical trials supporting successful new drug applications: A literature analysis","volume":"5","author":"Lee","year":"2008","journal-title":"PLoS Med"},{"key":"2021122703520952500_B17","doi-asserted-by":"crossref","first-page":"g6870","DOI":"10.1136\/bmj.g6870","article-title":"Discontinuation and non-publication of surgical randomised controlled trials: Observational study","volume":"349","author":"Chapman","year":"2014","journal-title":"BMJ"},{"key":"2021122703520952500_B18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jama.2014.1361","article-title":"Prevalence, characteristics, and publication of discontinued randomized trials","volume":"311","author":"Kasenda","year":"2014","journal-title":"JAMA"},{"key":"2021122703520952500_B19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJMsa1409364","article-title":"Compliance with results reporting at ClinicalTrials.gov","volume":"372","author":"Anderson","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122703520952500_B20","doi-asserted-by":"crossref","first-page":"e101826","DOI":"10.1371\/journal.pone.0101826","article-title":"How frequently do the results from completed US clinical trials enter the public domain?\u2014A statistical analysis of the ClinicalTrials.gov database","volume":"9","author":"Saito","year":"2014","journal-title":"PLoS One"},{"key":"2021122703520952500_B21","volume-title":"FDAAA 801 Requirements"},{"key":"2021122703520952500_B22","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2007.14.6795","article-title":"Consistency of phase III clinical trial abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications","volume":"26","author":"Tam","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122703520952500_B23","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2010.33.3922","article-title":"Compendium of unpublished phase III trials in oncology: Characteristics and impact on clinical practice","volume":"29","author":"Tam","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122703520952500_B24","doi-asserted-by":"crossref","first-page":"g3058","DOI":"10.1136\/bmj.g3058","article-title":"Non-publication and delayed publication of randomized trials on vaccines: Survey","volume":"348","author":"Manzoli","year":"2014","journal-title":"BMJ"},{"key":"2021122703520952500_B25","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamainternmed.2013.136","article-title":"Time to publication among completed clinical trials","volume":"173","author":"Ross","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2021122703520952500_B26","doi-asserted-by":"crossref","DOI":"10.1038\/nature.2013.14286","article-title":"Half of US clinical trials go unpublished","volume-title":"Nature 10.1038\/nature.2013.14286","author":"Jones"},{"key":"2021122703520952500_B27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/SLA.0000000000000810","article-title":"Completion and publication rates of randomized controlled trials in surgery: An empirical study","volume":"262","author":"Rosenthal","year":"2015","journal-title":"Ann Surg"},{"key":"2021122703520952500_B28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/IAE.0b013e3181eef2ad","article-title":"Publication rates of registered clinical trials in macular degeneration","volume":"31","author":"Prenner","year":"2011","journal-title":"Retina"},{"key":"2021122703520952500_B29","doi-asserted-by":"crossref","first-page":"e1000034","DOI":"10.1371\/journal.pmed.1000034","article-title":"Inadequate dissemination of phase I trials: A retrospective cohort study","volume":"6","author":"Decullier","year":"2009","journal-title":"PLoS Med"},{"key":"2021122703520952500_B30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: Systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"2021122703520952500_B31","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/jama.289.4.454","article-title":"Scope and impact of financial conflicts of interest in biomedical research: S systematic review","volume":"289","author":"Bekelman","year":"2003","journal-title":"JAMA"},{"key":"2021122703520952500_B32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1600-6143.2005.01203.x","article-title":"Factors associated with publication following presentation at a transplantation meeting","volume":"6","author":"Glick","year":"2006","journal-title":"Am J Transplant"},{"key":"2021122703520952500_B33","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.279.19.1566","article-title":"Why review articles on the health effects of passive smoking reach different conclusions","volume":"279","author":"Barnes","year":"1998","journal-title":"JAMA"},{"key":"2021122703520952500_B34","first-page":"MR000033","article-title":"Industry sponsorship and research outcome","volume":"12","author":"Lundh","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122703520952500_B35","first-page":"MR000006","article-title":"Publication bias in clinical trials due to statistical significance or direction of trial results","volume-title":"Cochrane Database Syst Rev","author":"Hopewell","year":"2009"},{"key":"2021122703520952500_B36","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.2010.651","article-title":"Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes","volume":"303","author":"Boutron","year":"2010","journal-title":"JAMA"},{"key":"2021122703520952500_B37","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/annonc\/mds636","article-title":"Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer","volume":"24","author":"Vera-Badillo","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122703520952500_B38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122703520952500_B39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(15)70102-6","article-title":"Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Blay","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122703520952500_B40","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2004.07.199","article-title":"Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: Guidelines for improved reporting","volume":"22","author":"Krzyzanowska","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122703520952500_B41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1191\/1740774505cn091oa","article-title":"Abstracts presented at the American Society of Clinical Oncology conference: How completely are trials reported?","volume":"2","author":"Hopewell","year":"2005","journal-title":"Clin Trials"},{"key":"2021122703520952500_B42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jama.2014.10716","article-title":"Sharing and reporting the results of clinical trials","volume":"313","author":"Hudson","year":"2015","journal-title":"JAMA"},{"key":"2021122703520952500_B43","doi-asserted-by":"crossref","first-page":"13439","DOI":"10.1073\/pnas.1511912112","article-title":"Accelerating scientific publication in biology","volume":"112","author":"Vale","year":"2015","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0516","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0516","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/3\/261\/41927343\/oncolo_21_3_261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/3\/261\/41927343\/oncolo_21_3_261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T03:53:20Z","timestamp":1640577200000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/3\/261\/6401331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,17]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,2,17]]},"published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0516","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,3,1]]},"published":{"date-parts":[[2016,2,17]]}}}